• Careers
  • News
  • Publications
  • Contact Us
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Collaborations
    • Careers
    • Contact Us
  • Therapeutic Areas
    • Oncology
    • Cystic Fibrosis
    • Publications
  • Programs
    • Pipeline
    • Glutaminase Inhibitor Telaglenastat
    • Arginase Inhibitor Oncology
    • Arginase Inhibitor
      Cystic Fibrosis
    • CD73 Inhibitor
      CB-708
    • IL4I1 Inhibitor
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access
  • Media & Investors
    • Corporate Profile
    • Press Releases
    • Event & Presentations
    • Stock Information
    • Financial Information
      • Overview
      • SEC Filings
      • Ownership Summary
    • Analyst Coverage
    • Corporate Governance
      • Highlights
      • Board of Directors
      • Management Team
      • Committee Composition
    • Shareholder Services
      • Investor FAQs
      • E-mail Alerts
    • Proxy & Annual Report
    • Contact Us
  • Careers
  • News
  • Publications
  • Contact Us

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Targeting cancer, differently.

Our onco-metabolism approach brings
an enhanced perspective to cancer.

Learn More

Development Pipeline

Calithera is pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.

Learn More

Development Pipeline

Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.

Learn More

Culture

Therapeutic Areas

Recent News

January 11, 2021

INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

January 5, 2021

Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

January 4, 2021

Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint

December 31, 2020

Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 2, 2020

Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View All
Company
  • About Us
  • Management Team
  • Board of Directors
  • Collaborations
  • Careers
  • Contact Us
Therapeutic Areas
  • Oncology
  • Cystic Fibrosis
  • Publications
Programs
  • Pipeline
  • Glutaminase Inhibitor Telaglenastat (CB-839)
  • Arginase Inhibitor Oncology
  • Arginase Inhibitor Cystic Fibrosis
  • CD73 Inhibitor CB-708
  • IL4I1 Inhibitor
Clinical Trials
  • Clinical Trial Overview
  • Expanded Access
Media & Investors
  • Corporate Profile
  • Press Release
  • Events & Presentations
  • Stock Information
  • Financial Information
  • Analyst Coverage
  • Corporate Governance
  • Shareholder Services
  • Proxy & Annual Report
  • Contact Us
© 2021 Calithera Biosciences, Inc. All rights reserved.
ETHICS & COMPLIANCEPRIVACY POLICYLEGAL TERMS OF USE
  • Contact Us
  • News
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.